Comparative study of high-dose ciclesonide and fluticasone on small airway in asthmatics

Comparative study of high-dose ciclesonide and fluticasone on small airway in asthmatics - Comparison of ciclesonide and fluticasone on small airway in asthmatics

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002665

Enrollment

Registered

2009-10-25

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

A) ciclesonide (800mcg/, 14days)-28days washout-fluticasone (800mcg/, 14days) B) fluticasone (800mcg/, 14days)-28days washout-ciclesonide (800mcg/, 14days)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Asthma is diagnosed in based on GINA 2006. 2. PC20 to methacholine < 16mg/mL. 3. non-smoker 4. stable status (>4wks)

Exclusion criteria

Exclusion criteria: 1. Inhaled, oral and injective corticosteroids, leukotriene receptor antagonists, inhaled, oral and transdermal long acting beta2 agonists,sodiumchromoglicate, xanthine, immunosuppressive agents, and anti-allergic agents (include anti-IgE antibody) is used 4wks prior to screening. 2. Respiratory infections (within 4wks) 3. Other underlying diseases 4. Any psychological disease 5. Pregnacy

Design outcomes

Primary

Measure	Time frame
Improvement of lung function and respiratory resistance	—

Secondary

Measure	Time frame
Improvement of small airway inflammation and the frequency of adverse events	—

Countries

Japan

Contacts

Public ContactTomotaka Kawayama

Kurume University School of Medicine Department of Medicine, Division of Respirology, Neurology, and Rheumatology

kawayama_tomotaka@med.kurume-u.ac.jp0942-31-7560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026